Black Rock Inc. Forte Biosciences, Inc. Transaction History

Black Rock Inc.

$4.35 Trillion
Q2 2024

A detailed history of Black Rock Inc. transactions in Forte Biosciences, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 174,858 shares of FBRX stock, worth $3.19 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

174,858

Previous 174,858 -0.0%

Holding current value

$3.19 Million

Previous $122,000 22.95%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$0.48 - $0.85 $3,583 - $6,346	-7,466 Reduced 4.09%	174,858 $122,000
Q4 2023 Feb 13, 2024	BUY	$0.38 - $0.82 $60 - $131	160 Added 0.09%	182,324 $149,000
Q3 2023 Nov 13, 2023	SELL	$0.65 - $1.04 $105 - $168	-162 Reduced 0.09%	182,164 $120,000
Q2 2023 Aug 11, 2023	SELL	$0.98 - $1.11 $8,899 - $10,079	-9,081 Reduced 4.74%	182,326 $189,000
Q1 2023 May 12, 2023	SELL	$0.98 - $1.06 $20,059 - $21,697	-20,469 Reduced 9.66%	191,407 $193,000
Q4 2022 Feb 13, 2023	SELL	$0.96 - $28.0 $177 - $5,180	-185 Reduced 0.09%	211,876 $211,000
Q3 2022 Nov 14, 2022	SELL	$1.06 - $27.75 $2,100 - $55,000	-1,982 Reduced 0.93%	212,061 $226,000
Q2 2022 Aug 12, 2022	SELL	$1.07 - $1.55 $633,410 - $917,556	-591,972 Reduced 73.44%	214,043 $278,000
Q1 2022 May 12, 2022	SELL	$1.21 - $2.24 $13,368 - $24,747	-11,048 Reduced 1.35%	806,015 $1.18 Million
Q4 2021 Feb 10, 2022	BUY	$2.02 - $3.36 $91,580 - $152,332	45,337 Added 5.87%	817,063 $1.75 Million
Q3 2021 Nov 09, 2021	SELL	$2.96 - $36.67 $10,043 - $124,421	-3,393 Reduced 0.44%	771,726 $2.28 Million
Q2 2021 Aug 11, 2021	BUY	$31.5 - $42.5 $24.4 Million - $32.9 Million	775,119 New	775,119 $26.1 Million

Others Institutions Holding FBRX

# of Institutions

Shares Held

175K

Call Options Held

Put Options Held

View Full List

About Forte Biosciences, Inc.

Ticker FBRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,340,300
Market Cap $371M
Description
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.

More about FBRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account